Alnylam宣布公司联合创始人、行业泰斗、长期董事会成员Phillip A. Sharp博士退休-动脉网

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

阿里拉姆制药等信源发布 2025-03-05 20:07



可切换为仅中文







CAMBRIDGE, Mass.

马萨诸塞州剑桥市

--(BUSINESS WIRE)--Mar. 5, 2025--

--（商业资讯）--2025年3月5日--

Alnylam Pharmaceuticals, Inc.

Alnylam制药公司

(Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr.

(Nasdaq: ALNY)，领先的RNAi治疗公司，今天宣布Dr.退休。

Phillip A. Sharp

菲利普·A·夏普

, Ph.D., from the Company’s Board of Directors, effective as of

，博士，从公司董事会离职，自生效日起

May 8, 2025

2025年5月8日

。

Dr. Sharp

夏普博士

has served as a key advisor to

一直担任关键顾问

Alnylam

阿尔尼拉姆

since he co-founded the Company in 2002.

自他于2002年共同创立公司以来。

Dr. Sharp

夏普博士

will remain a member of the

将仍然是

Alnylam Scientific Advisory Board

Alnylam科学顾问委员会

。

“Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam’s founding and the development of a transformative new class of medicines,” said

“菲尔帮助开创了RNAi革命，激发了导致Alnylam成立和一类变革性新药开发的科学合作，”

Yvonne Greenstreet

伊冯·格林斯特里特

, MBChB, Chief Executive Officer of

，医学学士，首席执行官

Alnylam

阿尔尼拉姆

. “He has provided invaluable guidance over the past twenty-two years that has shaped the remarkable company we have built. On behalf of

“在过去的二十二年里，他提供了宝贵的指导，塑造了我们建立的卓越公司。我谨代表

Alnylam

阿尔尼拉姆

– and in honor of the tens of thousands of patients worldwide who have benefitted from RNAi therapeutics – I want to thank Phil for his incredible vision and lasting impact on the field of medicine.”

“——为了全世界成千上万从中受益的患者，我要感谢Phil的远见卓识和对医学领域的持久影响。”

“Phil has made so many important scientific discoveries and his role at

“菲尔做出了如此多重要的科学发现，他在

Alnylam

阿尔尼拉姆

has been a critical one,” said

“一直是至关重要的一点，”

Amy W. Schulman

艾米·W·舒尔曼

, Chair of the Alnylam Board of Directors. “The Board and I want to thank him – we are so grateful to Phil for his role in shaping not only

，Alnylam董事会主席。“董事会和我本人要对他表示感谢——我们非常感激Phil在塑造公司方面所发挥的作用，不仅

Alnylam

阿尔尼拉姆

but also an entire industry.”

而且是一个完整的产业。

Dr. Sharp

夏普博士

is a distinguished scientific leader who holds a multitude of positions and honors throughout academia and industry. He was awarded a Nobel Prize in Physiology or Medicine in 1993 for the discovery of RNA splicing. Additionally, he was awarded the 2004 National Medal of Science and the

是一位杰出的科学领袖，在学术界和工业界担任众多职位并获得诸多荣誉。他因发现RNA剪接而于1993年获得诺贝尔生理学或医学奖。此外，他还获得了2004年美国国家科学奖章和

American Association for Cancer Research

美国癌症研究协会

(AACR) Award for Lifetime Achievement in

(AACR) 终身成就奖

Cancer Research

癌症研究

in 2020.

2020年。

Dr. Sharp

夏普博士

is an Institute Professor Emeritus of the

是该学院的荣休教授

Koch Institute for Integrative Cancer Research

科赫综合癌症研究所

在

MIT

麻省理工学院

and the Founding Director of the

以及创始董事

McGovern Institute for Brain Research

麦戈文脑研究所

在

MIT

麻省理工学院

. He is a member of the

。他是

National Academy of Sciences

美国国家科学院

, the

，这个

Institute of Medicine

医学院

, and the

，以及

American Academy of Arts and Sciences

美国艺术与科学院

. In addition to co-founding

. 除了共同创立之外

Alnylam

阿尔尼拉姆

，

Dr. Sharp

夏普博士

also co-founded Biogen and has served as a director for numerous other biotechnology companies.

还共同创立了百健公司，并在许多其他生物技术公司担任董事。

About RNAi

关于RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine.

RNAi（RNA干扰）是一种天然的细胞基因沉默过程，代表了当今生物学和药物开发中最有前途且进展最快的前沿领域之一。它的发现被誉为“每十年左右才会出现一次的重大科学突破”，并因其重要性而荣获2006年诺贝尔生理学或医学奖。

By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise .

通过利用我们细胞中发生的自然生物学过程RNAi，一类被称为RNAi治疗药物的新药已经成为现实。小干扰RNA（siRNA）是介导RNAi的分子。

Alnylam's

阿尔尼拉姆的

RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. .

RNAi治疗平台通过有效沉默编码致病或疾病通路蛋白的信使RNA（mRNA）——即遗传前体——从而阻止这些蛋白质的生成，功能优先于当今的药物。这是一种具有革命性的方法，有望改变遗传性疾病和其他疾病的患者护理方式。

About

关于

Alnylam Pharmaceuticals

阿尔尼拉姆制药公司

Alnylam

阿尔尼拉姆

(Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines.

(Nasdaq: ALNY) 已引领将RNA干扰（RNAi）转化为一类全新创新药物的开发，这些药物有潜力改变那些患有罕见和常见但未满足需求疾病患者的生活。基于诺贝尔奖获奖科学，RNAi疗法代表了一种强大且经过临床验证的方法，能够产生变革性的药物。

Since its founding in 2002, .

自 2002 年成立以来，。

Alnylam

阿尔尼拉姆

has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO

已经引领了RNAi革命，并继续实现一个大胆的愿景，将科学可能性变为现实。Alnylam的商业化RNAi治疗产品是ONPATTRO。

(patisiran), AMVUTTRA

(patisiran)，AMVUTTRA

(vutrisiran), GIVLAARI

(vutrisiran)，GIVLAARI

(givosiran), OXLUMO

(吉沃西兰)，OXLUMO

(lumasiran), and Leqvio

(lumasiran)，以及Leqvio

(inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis.

由Alnylam的合作伙伴诺华公司开发和商业化。

Alnylam

阿尔尼拉姆

has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.

拥有一个包含多种在研药物的深厚管线，其中多个候选产品正处于后期开发阶段。

Alnylam

阿尔尼拉姆

is executing on its “

正在执行其“

Alnylam P

阿尼拉姆制药公司

x25

” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.

“通过可持续创新和卓越的财务表现，为全球患者提供罕见病和常见病的变革性药物的战略，从而打造领先的生物技术形象。”

Alnylam

阿尔尼拉姆

is headquartered in

总部位于

Cambridge, MA.

马萨诸塞州剑桥市。

For more information about our people, science and pipeline, please visit

有关我们的人才、科学和产品线的更多信息，请访问

www.alnylam.com

and engage with us on X (formerly Twitter) at

并在X（原推特）上与我们互动